Molecular mechanisms underlying the antimetastatic activity of bufalin (Review)

  • Authors:
    • Jie Wang
    • Yue Xia
    • Qingshong Zuo
    • Teng Chen
  • View Affiliations

  • Published online on: March 21, 2018     https://doi.org/10.3892/mco.2018.1591
  • Pages:631-636
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Bufalin is a monomer compound extract from Chansu, which is a traditional Chinese medicine obtained from the skin and parotid venom glands of toads, such as Bufo bufo gargarizans Cantor and Bufo melanostictus Schneider. Chansu had been used in traditional Chinese medicine for >1,000 years due to its cardiac, anti-inflammatory and anticancer properties. Previous studies identified bufalin as the main anticancer compound of Chansu, and recent evidence has corroborated its anticancer properties. Bufalin inhibits cancer cell proliferation, induces cell cycle arrest, induces cancer cell apoptosis, inhibits neovascularization, induces cell differentiation, inhibits cancer metastasis and invasion, and enhances chemotherapeutic drug sensitivity. However, the function and mechanism of bufalin in metastatic cancer cells have not yet been expounded. The aim of the present review was to discuss the recent progress and prospects of bufalin in the prevention of cancer metastasis, particularly in inhibiting epithelial-to-mesenchymal transition.

Related Articles

Journal Cover

May 2018
Volume 8 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, J., Xia, Y., Zuo, Q., & Chen, T. (2018). Molecular mechanisms underlying the antimetastatic activity of bufalin (Review). Molecular and Clinical Oncology, 8, 631-636. https://doi.org/10.3892/mco.2018.1591
MLA
Wang, J., Xia, Y., Zuo, Q., Chen, T."Molecular mechanisms underlying the antimetastatic activity of bufalin (Review)". Molecular and Clinical Oncology 8.5 (2018): 631-636.
Chicago
Wang, J., Xia, Y., Zuo, Q., Chen, T."Molecular mechanisms underlying the antimetastatic activity of bufalin (Review)". Molecular and Clinical Oncology 8, no. 5 (2018): 631-636. https://doi.org/10.3892/mco.2018.1591